News & Events about Gamida Cell Ltd.
Thinking about buying stock in CNS Pharmaceuticals, Dermata Therapeutics, XPO, Gamida Cell, or Kingsoft Cloud? Thinking about buying stock in CNS Pharmaceuticals, Dermata Therapeutics, XPO, Gamida Cell, or Kingsoft Cloud? PR Newswire NEW YORK, April 20, 2023 NEW YORK, April 20, 2023 /PRNewswire...
Business Wire
3 months ago
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that two oral presentations and a poster presentation highlighting Gamida Cells investigational product candidates, omidubicel and GDA-201, were shared at the 2023 Tandem...
Ticker Report
6 months ago
Gamida Cell (NASDAQ:GMDA Get Rating) had its price objective cut by equities researchers at Needham Company LLC from $9.00 to $8.00 in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm currently has a buy rating on the stock. Needham &#...
Business Wire
6 months ago
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that members of the management team will present at the following upcoming investor conferences: 34th Annual Piper...
Business Wire
7 months ago
Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today announced encouraging preclinical data on GDA-501, a genetically modified NAM (nicotinamide) Natural Killer (NK...